{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:19:53Z","timestamp":1780755593876,"version":"3.54.1"},"reference-count":32,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1507\/endocrj.ej24-0227","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T22:11:49Z","timestamp":1718921509000},"page":"895-906","source":"Crossref","is-referenced-by-count":3,"title":["Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) &lt;i&gt;via&lt;\/i&gt; retrospective analyses in Okinawa, Japan"],"prefix":"10.1507","volume":"71","author":[{"given":"Ken-ichiro","family":"Honma","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriyuki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Teruya","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Yabiku","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Ishiki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yonaha","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Chinen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsugumi","family":"Uema","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2445-1047","authenticated-orcid":false,"given":"Hiroaki","family":"Masuzaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 K\u00e4yser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, et al. (2016) Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 101: 2826\u20132835.","DOI":"10.1210\/jc.2016-1472"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hannemann A, Wallaschofski H (2012) Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies\u2014a review of the current literature. Horm Metab Res 44: 157\u2013162.","DOI":"10.1055\/s-0031-1295438"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Burrello J, Monticone S, Losano I, Cavagli\u00e0 G, Buffolo F, et al. (2020) Prevalence of hypokalemia and primary aldosteronism in 5,100 patients referred to a tertiary hypertension unit. Hypertension 75: 1025\u20131033.","DOI":"10.1161\/HYPERTENSIONAHA.119.14063"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Savard S, Amar L, Plouin PF, Steichen O (2013) Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62: 331\u2013336.","DOI":"10.1161\/HYPERTENSIONAHA.113.01060"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, et al. (2018) Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension 71: 530\u2013537.","DOI":"10.1161\/HYPERTENSIONAHA.117.10263"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, et al. (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6: 41\u201350.","DOI":"10.1016\/S2213-8587(17)30319-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045\u20131050.","DOI":"10.1210\/jc.2003-031337"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, et al. (2018) Aldosterone LC-MS\/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism. J Clin Endocrinol Metab 103: 3965\u20133973.","DOI":"10.1210\/jc.2018-01041"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Nishikawa T, Omura M, Kawaguchi M, Takatsu A, Satoh F, et al. (2016) Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood. Endocr J 63: 1065\u20131080.","DOI":"10.1507\/endocrj.EJ16-0304"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Morimoto R, Ono Y, Tezuka Y, Kudo M, Yamamoto S, et al. (2017) Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay. Hypertension 70: 334\u2013341.","DOI":"10.1161\/HYPERTENSIONAHA.117.09078"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Teruyama K, Naruse M, Tsuiki M, Kobayashi H (2022) Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism. J Hum Hypertens 36: 77\u201385.","DOI":"10.1038\/s41371-020-00465-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Li T, Ma Y, Zhang Y, Liu Y, Fu T, et al. (2019) Feasibility of screening primary aldosteronism by aldosterone-to-direct renin concentration ratio derived from chemiluminescent immunoassay measurement: diagnostic accuracy and cutoff value. Int J Hypertens 2019: 2195796.","DOI":"10.1155\/2019\/2195796"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, et al. (2022) Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 69: 327\u2013359.","DOI":"10.1507\/endocrj.EJ21-0508"},{"key":"14","unstructured":"14 The taskforce for the survey and standardization of the guidelines for primary aldosteronism (2016) Consensus statement on the clinical practice of primary aldosteronism in Japan. Folia Endocrinol Japon 92: 1\u201349 (In Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nishikawa T, Satoh F, Takashi Y, Yanase T, Itoh H, et al. (2022) Comparison and commutability study between standardized liquid chromatography-mass spectrometry\/mass spectrometry (LC-MS\/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood. Endocr J 69: 45\u201354.","DOI":"10.1507\/endocrj.EJ21-0278"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Ozeki Y, Tanimura Y, Nagai S, Nomura T, Kinoshita M, et al. (2021) Development of a new chemiluminescent enzyme immunoassay using a two-step sandwich method for measuring aldosterone concentrations. Diagnostics (Basel) 11: 433.","DOI":"10.3390\/diagnostics11030433"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, et al. (2009) Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 151: 329\u2013337.","DOI":"10.7326\/0003-4819-151-5-200909010-00007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, et al. (2012) The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 97: 1606\u20131614.","DOI":"10.1210\/jc.2011-2830"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ceral J, Solar M, Krajina A, Ballon M, Suba P, et al. (2010) Cap J. Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results. Eur J Endocrinol 162: 101\u2013107.","DOI":"10.1530\/EJE-09-0217"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, et al. (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101: 1889\u20131916.","DOI":"10.1210\/jc.2015-4061"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M, et al. (2018) Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol Metab 103: 3620\u20133629.","DOI":"10.1210\/jc.2018-00059"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48: 452\u2013458.","DOI":"10.1038\/bmt.2012.244"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, et al. (2004) Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 50: 1650\u20131655.","DOI":"10.1373\/clinchem.2004.033159"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Rossi GP, Ceolotto G, Rossitto G, Seccia TM, Maiolino G, et al. (2016) Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin Chem Lab Med 54: 1441\u20131450.","DOI":"10.1515\/cclm-2015-1094"},{"key":"25","unstructured":"25 Conn JW (1955) Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45: 3\u201317."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A (2018) Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 3: 768\u2013774.","DOI":"10.1001\/jamacardio.2018.2003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A (2018) Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72: 658\u2013666.","DOI":"10.1161\/HYPERTENSIONAHA.118.11568"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A (2018) Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 6: 51\u201359.","DOI":"10.1016\/S2213-8587(17)30367-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045\u20131050.","DOI":"10.1210\/jc.2003-031337"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Ohno Y, Naruse M, Beuschlein F, Schreiner F, Parasiliti-Caprino M, et al. (2021) Adrenal venous sampling-guided adrenalectomy rates in primary aldosteronism: results of an international cohort (AVSTAT). J Clin Endocrinol Metab 106: e1400\u2013e1407.","DOI":"10.1210\/clinem\/dgaa706"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Kobayashi H, Nakamura Y, Abe M, Tanabe A, Sone M, et al. (2023) Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism. Endocr J 70: 489\u2013500.","DOI":"10.1507\/endocrj.EJ22-0585"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, et al. (2003) Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 88: 2489\u20132494.","DOI":"10.1210\/jc.2002-021476"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/9\/71_EJ24-0227\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T04:14:01Z","timestamp":1725682441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/9\/71_EJ24-0227\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0227","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"EJ24-0227"}}